ZA200810863B - Humanized anti-human osteopontin antibody - Google Patents

Humanized anti-human osteopontin antibody

Info

Publication number
ZA200810863B
ZA200810863B ZA200810863A ZA200810863A ZA200810863B ZA 200810863 B ZA200810863 B ZA 200810863B ZA 200810863 A ZA200810863 A ZA 200810863A ZA 200810863 A ZA200810863 A ZA 200810863A ZA 200810863 B ZA200810863 B ZA 200810863B
Authority
ZA
South Africa
Prior art keywords
human osteopontin
humanized anti
osteopontin antibody
antibody
human
Prior art date
Application number
ZA200810863A
Other languages
English (en)
Inventor
Nobuchika Yamamoto
Fumihiko Sakai
Hirofumi Higuchi
Masaharu Torikai
Toshihiro Nakashima
Original Assignee
Astellas Pharma Inc
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Chemo Sero Therapeut Res Inst filed Critical Astellas Pharma Inc
Publication of ZA200810863B publication Critical patent/ZA200810863B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200810863A 2006-05-31 2008-12-23 Humanized anti-human osteopontin antibody ZA200810863B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006152892 2006-05-31

Publications (1)

Publication Number Publication Date
ZA200810863B true ZA200810863B (en) 2010-08-25

Family

ID=38778682

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810863A ZA200810863B (en) 2006-05-31 2008-12-23 Humanized anti-human osteopontin antibody

Country Status (17)

Country Link
US (1) US7807161B2 (de)
EP (1) EP2025749B8 (de)
JP (1) JP4064441B2 (de)
KR (1) KR20090024748A (de)
CN (1) CN101495632B (de)
AT (1) ATE553130T1 (de)
AU (1) AU2007268591A1 (de)
BR (1) BRPI0711229A2 (de)
CA (1) CA2653661A1 (de)
ES (1) ES2384350T3 (de)
IL (1) IL195503A0 (de)
MX (1) MX2008015309A (de)
NO (1) NO20085282L (de)
RU (1) RU2429016C2 (de)
TW (1) TW200813087A (de)
WO (1) WO2007139164A1 (de)
ZA (1) ZA200810863B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711882C (en) 2008-01-11 2016-07-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Improved humanized anti-human .alpha.9-integrin antibody
JP5339748B2 (ja) * 2008-03-11 2013-11-13 国立大学法人北海道大学 ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
CN102027013B (zh) * 2008-04-24 2015-01-14 株式会社遗传科技 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用
JP5765814B6 (ja) 2009-10-21 2018-06-27 国立大学法人広島大学 インテグリンα８β１特異的モノクローナル抗体
WO2012050646A2 (en) 2010-06-29 2012-04-19 The Trustees Of The University Of Pennsylvania Biomimetic chemical sensors using nanoelectronic readout of olfactory receptors
WO2013033359A1 (en) * 2011-08-31 2013-03-07 The Trustees Of The University Of Pennsylvania Carbon nanotube biosensors and related methods
WO2014061783A1 (ja) 2012-10-19 2014-04-24 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US11415546B2 (en) 2014-09-05 2022-08-16 The Trustees Of The University Of Pennsylvania Volatile organic compound-based diagnostic systems and methods
EP3482096B1 (de) 2016-07-06 2023-02-22 Dana Automotive Systems Group, LLC Verbindungsanordnung zur schnellkupplung von achse und propellerwelle
KR20180000875U (ko) 2016-09-21 2018-03-29 전은희 조명 모듈
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
US20230272058A1 (en) * 2021-07-02 2023-08-31 Washington University Compositions and methods for preventing acute kidney injury-induced acute lung injury (aki-ali)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994020632A1 (fr) 1993-03-11 1994-09-15 Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute Anticorps monoclonal dirige contre le vih
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
CA2267620A1 (en) * 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
US20040234524A1 (en) 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
CA2453662A1 (en) * 2001-07-19 2003-01-30 Stefan Ewert Modification of human variable domains
JPWO2003027151A1 (ja) * 2001-09-25 2005-01-06 株式会社 免疫生物研究所 組換え抗オステオポンチン抗体およびその用途
WO2006043954A1 (en) 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
US7456260B2 (en) * 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
EP1637159A4 (de) 2003-05-23 2009-01-21 Immuno Biological Lab Co Ltd Immunkompetenter zellaktivierungshemmer und seine verwendung
JP2006152892A (ja) 2004-11-29 2006-06-15 Anest Iwata Corp 気体吸排機械
CA2596925C (en) * 2005-02-08 2017-07-04 Km Biologics Co., Ltd. Method for improving expression level and stability of antibody

Also Published As

Publication number Publication date
EP2025749A1 (de) 2009-02-18
RU2429016C2 (ru) 2011-09-20
EP2025749B1 (de) 2012-04-11
US7807161B2 (en) 2010-10-05
ES2384350T3 (es) 2012-07-04
JP4064441B2 (ja) 2008-03-19
AU2007268591A1 (en) 2007-12-06
RU2008152769A (ru) 2010-07-20
IL195503A0 (en) 2011-08-01
EP2025749A4 (de) 2009-12-16
CN101495632B (zh) 2011-08-03
EP2025749B8 (de) 2012-05-23
CN101495632A (zh) 2009-07-29
WO2007139164A1 (ja) 2007-12-06
BRPI0711229A2 (pt) 2013-01-08
NO20085282L (no) 2009-02-26
MX2008015309A (es) 2009-03-02
TW200813087A (en) 2008-03-16
KR20090024748A (ko) 2009-03-09
ATE553130T1 (de) 2012-04-15
CA2653661A1 (en) 2007-12-06
JP2008005836A (ja) 2008-01-17
US20090053212A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
ZA200810863B (en) Humanized anti-human osteopontin antibody
WO2005092926A3 (en) Reducing the risk of human and anti-human antibodies through v gene manipulation
ATE535545T1 (de) Chimäre und humanisierte monoklonale antikörper gegen interleukin-13
HRP20181218T1 (hr) Humanizirana anti-il-6 protutijela, pripravci, postupci pripreme i upotrebe
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
ATE520716T1 (de) Humanisierter anti-cd4-antikörper mit immunsuppressiven eigenschaften
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
NZ585622A (en) Hepatitis c virus antibodies
ATE512986T1 (de) Antikörper gegen clostridium difficile-toxine und ihre verwendung
TWI370136B (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
EA200901500A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
IL183939A0 (en) Anti - il - 12 antibodies, epitopes, compositions, methods and uses
WO2003078600A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2007087289A3 (en) Anti-fcrn antibodies for treatement of auto/allo immune conditions
WO2006061723A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
DK1519748T3 (da) Mikropartikler med CD28-specifikke monoklonale antistoffer
WO2011112850A3 (en) Humanized and chimeric anti-properdin antibodies
WO2008094942A3 (en) Humanized antibodies against cxcr3
MX2008002161A (es) Anticuerpos quimericos con regiones de primate del nuevo mundo.
EP2143734A4 (de) Funktionelles epitop von osteopontin, monoklonaler antiosteoponinantikörper und verwendung davon
DK1907854T3 (da) Monoklonale antistoffer, hybridomcellelinjer, fremgangsmåder og kits til detektion af phytase
BRPI0509495A2 (pt) anticorpo humanizado
WO2006001965A3 (en) Reducing the risk of human anti-human antibodies through v gene manipulation
DK1899377T3 (da) Humaniserede antistoffer, der er specifikke for NOGO-A, og farmaceutiske anvendelser deraf.